http://glioblastomatreatments.wiki:80/index.php
type: Ontology
creation date: 2026-08-27T01:38:21-07:00
imports: http://semantic-mediawiki.org/swivt/1.0

ICT-107
type: Subject
type: http://glioblastomatreatments.wiki/index.php
page: http://glioblastomatreatments.wiki:80/index.php
wiki namespace: 0
wiki page content language: en
has OS with: http://glioblastomatreatments.wiki/index.php
has OS without: http://glioblastomatreatments.wiki/index.php
has PFS with: http://glioblastomatreatments.wiki/index.php
has PFS without: http://glioblastomatreatments.wiki/index.php
has toxicity explanation: The vaccine has shown a benign safety profile with minimal severe adverse effects, making it a potentially safer alternative or complement to existing GBM treatments.
has toxicity level: http://glioblastomatreatments.wiki/index.php
has usefulness explanation: http://glioblastomatreatments.wiki/index.php
has usefulness rating: http://glioblastomatreatments.wiki/index.php
has clinical trial explanation: http://glioblastomatreatments.wiki/index.php
has clinical trial phase: http://glioblastomatreatments.wiki/index.php
has common side effects: http://glioblastomatreatments.wiki/index.php
has treatment name: http://glioblastomatreatments.wiki/index.php
processing error: http://glioblastomatreatments.wiki/index.php
wiki page modification date: 2025-01-18T08:27:43Z
modification date#aux: 2460693.852581
wiki page sort key: ICT-107

http://glioblastomatreatments.wiki/index.php
type: Subject
master page: ICT-107
wiki namespace: 0
has improper value for: http://glioblastomatreatments.wiki/index.php
processing error message: [2,"smw-datavalue-wikipage-property-invalid-title","Has original text","One disadvantage of the DCVax approach is that it requires that brain tissue be extracted\nfrom individual patients in order to make the vaccine. An alternative approach has been\nused by Dr. Black\u2019s team at Cedars Sinai. Dendritic cells are still drawn from the\nperipheral blood of individual patients, but instead of tumor tissue lysate being mixed\nwith those cells, a collection of six proteins typical of of GBMs is mixed with the\n\ndendritic cells, creating an immune response to those antigens, with the mixture then\nreturned to the patient via vaccinations. In a phase I trial (158), 20 GBM patients (17\nnewly diagnosed, 3 with recurrent tumors) received three vaccinations two weeks apart.\nMedian PFS was 16.9 months, and median overall survival was 38 months. At the time of\nthe clinical trial report, six of the patients had shown no sign of tumor recurrence. A later\nfollow-up was reported in a Press release from ImmunoCellular Therapeutics (159), the\nbiotech company sponsoring the vaccine (now called ICT-107). Survival rate at three\nyears was 55%, with 38% of patients showing no evidence of recurrence, The most\n\nrecent update of the clinical trial (160), presented at the 2013 meeting of the World\nFederation of Neuro-oncology, reported that 7 of the original 16 patients in the trial were\nstill alive, with survivals ranging from 60 to 83 months. One additional patient who was\nstill tumor free after five years died from leukemia.\n\nCurrently ongoing is a randomized phase II trial, the interim results of which have\nrecently reported by ImmunoCellular Therapeutics (161). Despite the impressive results\ndescribed above, there was no statistically significant difference in median survival\nbetween the vaccine group and those treated with a placebo, although there was a\nnumerical 2-3 month advantage for the vaccine group. However there was a similar\ndifference in progression-free …
wiki page sort key: ICT-107# ERRa3f62c6665776505f0db7c26c19aebf1